Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

Ozempic and Mounjaro are key drugs for Novo Nordisk and Eli Lilly, respectively. Both treat most of the same conditions, and both are major drivers of earnings.

2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not

INDIANAPOLIS , Oct. 6, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor), and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid.  Presentation Highlights Verzenio (abemaciclib) In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.

Lilly Announces Details of Presentations at ESMO Congress 2023

Eli Lilly set out to launch four new products this year, but it is unlikely to do so. The company's regulatory roadblocks aren't deal-breakers for its medicines.

Should You Sell This Stock After Another Regulatory Headwind?

Intuitive Surgical

What Are The Best Stocks To Invest In? 2 Healthcare Stocks To Know

There have been relatively few big winners among pharma stocks so far in the 2020s. One big pharma stock stands out as the clear leader by roughly tripling over the last nearly four years.

Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)

INDIANAPOLIS , Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic KRAS mutations and Nectin-4, will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston. These programs are among the next slate of new oncology agents planned to enter clinical trials for Loxo@Lilly in 2024.

Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Eli Lilly's (LLY) acquisition of POINT Biopharma, if successfully closed, is likely to bolster its portfolio of cancer drugs.

Lilly (LLY) to Buy POINT Biopharma, Strengthen Cancer Portfolio

Mike Mason, the executive vice president and president of Lilly Diabetes & Obesity at Eli Lilly and Co (NYSE:LLY), is set to retire at the end of this year after a 34-year tenure with the pharmaceutical giant. Mason has been instrumental in the development and launch of Mounjaro, a blockbuster diabetes medication that has also seen off-label use for weight loss.

Eli Lilly exec behind diabetes blockbuster set retire

Eli Lilly and Co said on Wednesday that the head of its diabetes and obesity division, Mike Mason, will retire by the end of the year after more than three decades with the drugmaker.

Eli Lilly's head of diabetes and obesity unit to retire

INDIANAPOLIS , Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team. Mike Mason , executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company.

Lilly Announces Leadership Transitions

The pharmaceutical giant signed a deal to acquire cancer therapy developer Biopharma Global. Its asset-to-be is a developer of precision cancer therapies.

Why Eli Lilly Stock Was Looking Sickly Today

Bristol-Myers

Johnson & Johnson

Merck

Major drugmakers including Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and Merck & Co Inc (NYSE:MRK) have agreed to participate in the Inflation Reduction Act's (IRA's) Medicare Drug Price Negotiation Program, the Biden administration said on Tuesday. The Inflation Reduction Act of 2022 granted the ability for Medicare to negotiate drug prices directly with manufacturers with the aim of reducing the costs of medications for seniors and other Medicare beneficiaries.

Drugmakers agree to participate in Medicare price negotiations

Point Biopharma Global

Shares of POINT Biopharma Global (PNT) skyrocketed over 80% in early trading on Tuesday after Eli Lilly (LLY) agreed to buy the radiopharmaceutical firm for $1.4 billion to expand its cancer-fighting treatments.

Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies

Eli Lilly And Co  (NYSE: LLY ) stock is down 2.5% to trade at $525.97 at last check, after the pharma company announced the acquisition of Point Biopharma Global (PNT) for $1.4 billion in an all-cash deal, or roughly $12.50 per share.

Eli Lilly Stock Cools Despite Big Cancer Investment

Shares of Point Biopharma Global Inc (NASDAQ: PNT) close to doubled this morning after Eli Lilly & Co (NYSE: LLY) announced plans of acquiring the cancer treatment company. Details of Lilly-Point agreement Lilly is willing to pay about $1.4 billion for Point Biopharma that values each of its share at $12.

Point Biopharma stock nearly doubles on Eli Lilly deal

American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manu

Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion—A Nearly 90% Premium

Eli Lilly said Tuesday it will buy cancer specialist Point Biopharma Global for $1.4 billion, launching PNT stock to a two-year high.

Point Biopharma Stock Launches 84% On Eli Lilly's $1.4 Billion Takeover

Shares in Point Biopharma Global jumped 84% following the announcement that pharmaceutical giant Eli Lilly and Co (NYSE:LLY) will acquire the company for $1.4 billion (£1.03 billion). The acquisition allows Lilly to expand its portfolio of experimental cancer therapies, particularly in the area of radioligand treatments.

Point Biopharma shares storm ahead 84% after Eli Lily's $1.4bn bid

Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.

Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection

AbbVie

Amphenol

Broadcom

Bank of New York Mellon

CBRE Group

Cigna

Elevance Health Inc

KLA-Tencor

Lam Research

Microchip Technology

Mettler-Toledo

PPG Industries

Why settle for stocks limping to the finish line? Some investors found S&P 500 stocks that finish the year on a high note.

There's Still Time To Own 13 Stocks That Finish The Year Strong

Eli Lilly will acquire radiopharmaceutical company Point Biopharma Global for $12.50 a share.

Eli Lilly to Buy Point Biopharma for $1.4 Billion

Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday.

Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion

Point Biopharma Global, Inc.'s PNT, +0.22% stock was up 83.4% in premarket trading on Tuesday after Eli Lilly & Co. LLY, +0.22% said it will pay $12.50 a share to acquire the Indianapolis-based cancer treatment company for about $1.4 billion. The purchase price amounts to an 87% premium to Point Biopharma's closing price on Monday.

Point Biopharma Global's stock jumps more than 80% after Lilly merger deal

INDIANAPOLIS , Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope to a targeting molecule that delivers radiation directly to cancer cells, enabling significant anti-tumor efficacy while limiting the impact to healthy tissue.

Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies

Amgen

Novartis

Pfizer

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to participate in the talks by the Oct. 1 deadline.

News for Eli Lilly Stock (LLY)